261 related articles for article (PubMed ID: 10334520)
1. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis.
Sturm I; Petrowsky H; Volz R; Lorenz M; Radetzki S; Hillebrand T; Wolff G; Hauptmann S; Dörken B; Daniel PT
J Clin Oncol; 2001 Apr; 19(8):2272-81. PubMed ID: 11304781
[TBL] [Abstract][Full Text] [Related]
4. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Güner D; Sturm I; Hemmati P; Hermann S; Hauptmann S; Wurm R; Budach V; Dörken B; Lorenz M; Daniel PT
Int J Cancer; 2003 Feb; 103(4):445-54. PubMed ID: 12478659
[TBL] [Abstract][Full Text] [Related]
5. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
6. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
7. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer.
Gessner C; Liebers U; Kuhn H; Stiehl P; Witt C; Schauer J; Wolff G
Eur Respir J; 2002 Jan; 19(1):134-40. PubMed ID: 11843312
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
9. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
10. Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
Grabowski P; Sturm I; Schelwies K; Maaser K; Buhr HJ; Dörken B; Zeitz M; Daniel PT; Scherübl H
Int J Colorectal Dis; 2006 Apr; 21(3):221-30. PubMed ID: 16485142
[TBL] [Abstract][Full Text] [Related]
11. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma.
Bandoh N; Hayashi T; Kishibe K; Takahara M; Imada M; Nonaka S; Harabuchi Y
Cancer; 2002 Apr; 94(7):1968-80. PubMed ID: 11932899
[TBL] [Abstract][Full Text] [Related]
13. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
[TBL] [Abstract][Full Text] [Related]
14. p53 and related proteins in epithelial ovarian cancer.
Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
[TBL] [Abstract][Full Text] [Related]
15. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
Rau B; Sturm I; Lage H; Berger S; Schneider U; Hauptmann S; Wust P; Riess H; Schlag PM; Dörken B; Daniel PT
J Clin Oncol; 2003 Sep; 21(18):3391-401. PubMed ID: 12885834
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype.
De Angelis PM; Stokke T; Thorstensen L; Lothe RA; Clausen OP
Mol Pathol; 1998 Oct; 51(5):254-61. PubMed ID: 10193519
[TBL] [Abstract][Full Text] [Related]
18. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.
Brambilla E; Gazzeri S; Lantuejoul S; Coll JL; Moro D; Negoescu A; Brambilla C
Clin Cancer Res; 1998 Jul; 4(7):1609-18. PubMed ID: 9676834
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
